We are live on ! Find out more
ARNA

Arena Pharmaceuticals Inc

Delisted

ARNA was delisted on the 10th of March, 2022.

247 hedge funds and large institutions have $3.4B invested in Arena Pharmaceuticals Inc in 2020 Q2 according to their latest regulatory filings, with 59 funds opening new positions, 82 increasing their positions, 74 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 39 (+6)

118% more call options, than puts

Call options by funds: $44.6M | Put options by funds: $20.4M

97% more first-time investments, than exits

New positions opened: 59 | Existing positions closed: 30

76% more capital invested

Capital invested by funds: $1.93B → $3.4B (+$1.47B)

13% more funds holding

Funds holding: 219247 (+28)

11% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 74

Holders
247
Holders Change
+28
Holders Change %
+12.79%
% of All Funds
5.06%
Holding in Top 10
9
Holding in Top 10 Change
+6
Holding in Top 10 Change %
+200%
% of All Funds
0.18%
New
59
Increased
82
Reduced
74
Closed
30
Calls
$44.6M
Puts
$20.4M
Net Calls
+$24.1M
Net Calls Change
+$17M
Name Holding Trade Value Shares
Change
Change in
Stake
Primecap Management
26
Primecap Management
California
$34.9M -$1.4M -25,430 -4%
CTA
27
Carillon Tower Advisers
Florida
$34.9M -$6.11M -111,092 -17%
BM
28
Bridger Management
New York
$33.8M +$19.5M +354,996 +195%
Macquarie Group
29
Macquarie Group
Australia
$33.2M -$40.7K -739 -0.1%
HM
30
HealthCor Management
New York
$30.2M +$2.43M +44,120 +10%
Alyeska Investment Group
31
Alyeska Investment Group
Illinois
$29.2M -$19.3M -349,882 -43%
N
32
Nuveen
North Carolina
$28.6M -$5.98M -108,657 -19%
CS
33
Candriam SCA
Luxembourg
$28.6M +$3.15M +57,275 +14%
Wells Fargo
34
Wells Fargo
California
$27M +$3.53M +64,192 +18%
Charles Schwab
35
Charles Schwab
California
$23.5M +$3.04M +55,186 +17%
SAM
36
Sectoral Asset Management
Quebec, Canada
$22.8M +$20M +362,900 New
GGHC
37
Gilder Gagnon Howe & Co
New York
$19.8M +$17.3M +314,998 New
EMG
38
ETF Managers Group
New Jersey
$19.5M +$431K +7,830 +3%
RCAMU
39
Rothschild & Co Asset Management US
Connecticut
$17.9M +$15.6M +284,321 New
Holocene Advisors
40
Holocene Advisors
New York
$17.8M -$24.4M -443,618 -61%
LGM
41
Logos Global Management
California
$16.9M +$14.8M +268,500 New
FLAM
42
First Light Asset Management
Minnesota
$16.7M +$9.45M +171,761 +184%
Millennium Management
43
Millennium Management
New York
$16.6M +$7.89M +143,437 +119%
BNP Paribas Asset Management
44
BNP Paribas Asset Management
France
$16.5M +$14.4M +262,308 New
PHS
45
PFM Health Sciences
California
$16.5M -$26.8M -487,409 -65%
DCM
46
DAFNA Capital Management
California
$15.4M +$3.6M +65,500 +36%
Axa
47
Axa
France
$15.2M +$5.14M +93,461 +63%
PM
48
Prosight Management
Texas
$14.3M -$10.6M -192,390 -46%
JP Morgan Chase
49
JP Morgan Chase
New York
$13.9M -$4.49M -81,657 -27%
ACM
50
Atika Capital Management
New York
$13.5M +$3.25M +59,000 +38%

ARNA Hedge Fund Activity: Q2 2020 in Review

247 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Arena Pharmaceuticals Inc (ARNA) for Q2 2020, worth a combined $3.4B — up 76% from $1.93B a quarter earlier.

Buyers outnumbered sellers: 59 funds opened new ARNA positions and 30 closed out — a net gain of 29 holders — while 82 added to existing stakes and 74 trimmed.

The largest buyer was Alkeon Capital Management, adding an estimated $54.5M. The largest seller was Victory Capital Management, cutting an estimated $47M.

  • 247 institutional investors held Arena Pharmaceuticals Inc (ARNA) as of Q2 2020, up from 219 in Q1 2020.
  • Funds reported $3.4B of Arena Pharmaceuticals Inc stock for Q2 2020, up 76% quarter-over-quarter.
  • 59 funds opened new Arena Pharmaceuticals Inc positions in Q2 2020 and 30 closed out, a net change of +29 holders.
  • The largest Arena Pharmaceuticals Inc buyer in Q2 2020 was Alkeon Capital Management, an estimated $54.5M added.
  • The largest Arena Pharmaceuticals Inc seller in Q2 2020 was Victory Capital Management, an estimated $47M sold.

Based on aggregated 13F filings for Q2 2020.